Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Biotech/Pharma Business
-
By Jason Derry — Tanox Inc. has announced that its shareholders have approved Genentech's offer to acquire the company for $20 per share ($919 million). Tanox is a biotechnology company located in Houston, TX that focuses on discovery and development of biotherapeutics. Tanox's approved drug Xolair® (omalizumab) is the first anti-IgE antibody on…
-
It may be too late to sign up for "Launching a Biotech or Medical Device Start-Up: What Does it Take to be Successful?" a sold-out entrepreneurial education event hosted by the Illinois Technology Enterprise Center-Evanston on January 17, 2007, in Chicago, Illinois. However, if you're in the Chicago Metro area on Saturday, January 20, 2007,…
-
By Jason Derry — Research and Markets recently announced the availability of two new reports relating to the biotechnology industry: "Biotechnology in the United States" and "Biopartnering Strategies: Maximizing Returns from Biotechnology Deal-making." According to the Research and Markets website, "Biotechnology in the United States" provides data and analysis relating to trends and…
-
By Jason Derry — CytRx Corp. has announced that it has contributed its RNA interference portfolio to RXi Pharmaceuticals Corp. CytRx owns 85% of RXi while the remaining 15% will be owned by RXi's scientific advisory board. The members of the advisory board, subject to consent from each member's employer, include Craig C.…
-
By Jason Derry — Genentech and Seattle Genetics have announced an agreement involving the development and commercialization of a humanized monoclonal antibody for treating hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. The antibody, SGN-40, is currently in Phase I and II clinical trials. According to the press release, Seattle…
-
By Christopher P. Singer — In a January 2, 2007 press release, The Patent Board® announced that it will provide The Patent Scorecard to The Wall Street Journal on a weekly basis. The Wall Street Journal plans to publish the information every Tuesday in the "Money & Investing" section, and will be accessible…
-
By Jason Derry — Roche Holding AG has announced an agreement with Synosis Therapeutics in which Synosis will have rights to five drug candidates that Roche is no longer developing. Four of the drugs are in Phase I clinical trials. According to the Press Release, the drugs relate to schizophrenia, cognitive disorders, Parkinson's…
-
By Jason Derry — Elusys Therapeutics, Inc. has announced an exclusive license with Pfizer Inc. to collaborate in the development of new therapeutics for infectious diseases. The agreement relates to the use of Elusys' HP Antibody® technology. Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular…
-
By Jason Derry — Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc. have announced the intent to merge and form a new company that will focus on oncology and infectious disease. Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
-
By Jason Derry — Pharmacopeia and Wyeth have announced that the two companies have agreed to an exclusive license relating to the development and commercialization of therapeutics from Pharmacopeia's JAK3 inhibitor technology. Under the agreement, Pharmacopeia has the right to therapeutics relating to dermatological and ocular diseases by topical administration, while Wyeth has…
Patent Docs 